1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: POI-02818, NIP-02-005, NCT00131313
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: MCC-14178, NCT00361140
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: TPH/SCU-IMed 01/08, NCT00838019
|
|
4.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 to 70
Sponsor: Other
Protocol IDs: RPCI-RP-9815, NCI-V99-1527, NCT00003816, RP 98-15
|
|
5.
|
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: Levosta-CBF-02/04, NCT00215007
|
|
6.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 152CL201, NCT00391066
|
|
7.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 and over
Sponsor: NCI
Protocol IDs: RPCI-I-72806, I 72806, NCT00536601
|
|
8.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 19 to 70
Sponsor: Other
Protocol IDs: F080429003, UAB-0775, NCT00714259
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI
Protocol IDs: FHCRC-1813.00, 5666, NCT00075478
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Geriatric
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL9, EU-20561, AMGEN-GCLLSG-CLL9, EUDRACT-2005-003014-15, NCT00281892
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL7, EU-20559, ROCHE-GCLLSG-CLL7, EUDRACT-2005-003-018-14, NCT00275054
|
|
13.
|
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 55/05, ALLG SC01, NHMRC Project Grant 331305, NCT00163722
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: NCI
Protocol IDs: CBMTG-0601, NCT00438958
|
|
15.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-10501, CALGB-10501, NCT00513747
|
|
16.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 12 to 65
Sponsor: Other
Protocol IDs: PROGAST, NCT00180089
|
|
17.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 65
Sponsor: Other
Protocol IDs: CHRUT-LLC-2007-SA, LLC 2007 SA, CHRUT-PHRN05-CD, INCA-RECF0497, EUDRACT-2007-001015-28, NCT00645606
|
|
18.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 2 to 55
Sponsor: NCI, NHLBI
Protocol IDs: 385, BMT CTN 0402, U01 HL069294-05, NCT00406393
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML21283, 2008-001140-39, NCT00718549
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OMB110911, EudraCT 2008-004932-19, NCT00748189
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL10, CLL10, EUDRACT-2007-007587-21, EU-20883, ROCHE-GCLLSG-CLL10, NCT00769522
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-CLL-002, NCT00774345
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 110913, NCT00824265
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and ovr
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-CLL-008, Eudract #: 2008-003079-32, NCT00910910
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 72
Sponsor: NCI, Other
Protocol IDs: 09-073, NCT00928018
|
